- Home
- FCAP vs ACTU Comparison
FCAP vs ACTU Comparison
Compare FCAP & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCAP
- ACTU
- Stock Information
- Founded
- FCAP 1891
- ACTU 2015
- Country
- FCAP United States
- ACTU United States
- Employees
- FCAP N/A
- ACTU N/A
- Industry
- FCAP Savings Institutions
- ACTU
- Sector
- FCAP Finance
- ACTU
- Exchange
- FCAP Nasdaq
- ACTU NYSE
- Market Cap
- FCAP 140.8M
- ACTU 135.0M
- IPO Year
- FCAP 1999
- ACTU 2024
- Fundamental
- Price
- FCAP $37.78
- ACTU $7.26
- Analyst Decision
- FCAP
- ACTU Strong Buy
- Analyst Count
- FCAP 0
- ACTU 1
- Target Price
- FCAP N/A
- ACTU $20.00
- AVG Volume (30 Days)
- FCAP 30.1K
- ACTU 170.2K
- Earning Date
- FCAP 07-25-2025
- ACTU 09-23-2025
- Dividend Yield
- FCAP 3.07%
- ACTU N/A
- EPS Growth
- FCAP 9.31
- ACTU N/A
- EPS
- FCAP 3.93
- ACTU N/A
- Revenue
- FCAP $44,673,000.00
- ACTU N/A
- Revenue This Year
- FCAP N/A
- ACTU N/A
- Revenue Next Year
- FCAP N/A
- ACTU N/A
- P/E Ratio
- FCAP $9.61
- ACTU N/A
- Revenue Growth
- FCAP 9.48
- ACTU N/A
- 52 Week Low
- FCAP $28.50
- ACTU $5.47
- 52 Week High
- FCAP $53.85
- ACTU $11.99
- Technical
- Relative Strength Index (RSI)
- FCAP 34.19
- ACTU N/A
- Support Level
- FCAP $38.52
- ACTU N/A
- Resistance Level
- FCAP $39.59
- ACTU N/A
- Average True Range (ATR)
- FCAP 1.55
- ACTU 0.00
- MACD
- FCAP -0.30
- ACTU 0.00
- Stochastic Oscillator
- FCAP 15.01
- ACTU 0.00
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.